What is Theolytics?
Theolytics is an England-based biotechnology company dedicated to pioneering innovative oncolytic immunotherapy solutions for solid tumors, with a particular focus on ovarian cancer. Leveraging its proprietary ADENOVO discovery platform, the company engineers viruses to create highly targeted therapies designed to offer lasting cures and improve patient lives. Theolytics integrates deep expertise in virology, cancer biology, and immunology, fostering strategic partnerships with leading biopharmaceutical entities and attracting investment from prominent venture capital firms.
How much funding has Theolytics raised?
Theolytics has raised a total of $6.8M across 1 funding round:
Series A
$6.8M
Series A (2021): $6.8M with participation from Epidarex Capital, TAIHO VENTURES , LLC, and Oxford Sciences Enterprises
Key Investors in Theolytics
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm that focuses on building breakthrough life science companies in emerging hubs. They act as trusted partners to founders and co-investors, utilizing deep scientific and industry networks to create value.
TAIHO VENTURES , LLC
TAIHO VENTURES , LLC is an investor participating in the funding round, contributing to the company's strategic growth and development in the biotech sector.
Oxford Sciences Enterprises
Oxford Science Enterprises is an investment company established to found, fund, and build transformational businesses, leveraging a unique partnership with the University of Oxford to drive innovation in the life sciences.
What's next for Theolytics?
With the infusion of major enterprise-level capital and a recent strategic investment, Theolytics is well-positioned for significant growth and advancement in its therapeutic pipeline. This substantial backing is expected to fuel the expansion of its ADENOVO discovery platform, accelerate clinical development for its oncolytic immunotherapies, and potentially broaden its market reach. The company's trajectory suggests a move towards scaling operations and further solidifying its position as a key player in the competitive oncology landscape, aiming to bring its groundbreaking therapies to a wider patient population.
See full Theolytics company page
